Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors

被引：28
作者：
Hochhaus, A. [1 ]
机构：
[1] Heidelberg Univ, Med Klin 3, Fak Med, D-6800 Mannheim, Germany
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
10.1093/annonc/mdl273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：X274 / X279
页数：6
相关论文
共 40 条
[1]   Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha [J].
Bacher, U ;
Hochhaus, A ;
Berger, U ;
Hiddemann, W ;
Hehlmann, R ;
Haferlach, T ;
Schoch, C .
LEUKEMIA, 2005, 19 (03) :460-463
[2]   Imatinib and beyond - the new CML study IV - A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia [J].
Berger, U ;
Engelich, G ;
Reiter, A ;
Hochhaus, A ;
Hehlmann, R .
ANNALS OF HEMATOLOGY, 2004, 83 (04) :258-264
[3]   Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority [J].
Bumm, T ;
Müller, C ;
Al-Ali, HK ;
Krohn, K ;
Shepherd, P ;
Schmidt, E ;
Leiblein, S ;
Franke, C ;
Hennig, E ;
Friedrich, T ;
Krahl, R ;
Niederwieser, D ;
Deininger, MWN .
BLOOD, 2003, 101 (05) :1941-1949
[4]   Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α [J].
Cortes, J ;
Giles, F ;
O'Brien, S ;
Thomas, D ;
Garcia-Manero, G ;
Rios, MB ;
Faderi, S ;
Verstovsek, S ;
Ferrajoli, A ;
Freireich, EJ ;
Talpaz, M ;
Kantarjian, H .
BLOOD, 2003, 102 (01) :83-86
[5]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[6]   Imatinib as a paradigm of targeted therapies [J].
Druker, BJ .
ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 :1-+
[7]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[8]  
Gambacorti-Passerini C, 2003, CLIN CANCER RES, V9, P625
[9]   Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment [J].
Goldman, JM ;
Melo, JV .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1451-1464
[10]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
1234